Table 1. Baseline characteristics of Crohn's disease and ulcerative colitis patients initiating vedolizumab therapy.
| Crohn's disease | Total population (n=107) | MGH (n=46) | BWH (n=61) |
|---|---|---|---|
| Age – yrs | 39.7 (14.0) | 42.5 ± 14.5 | 37.6 ± 13.3 |
| Male sex - no (%) | 51 (47.7) | 25 (54.4) | 26 (42.6) |
| Duration of disease – yrs | 16.4 ± 10.6 | 16.0 ± 10.4 | 16.8 ± 10.8 |
| Current smoker - no. (%) | 13 (12.2) | 7 (15.2) | 6 (9.8) |
| Mean HBI score ‡ | 8.0 ± 6.9 | ||
| Mean C-reactive protein -mg/litre | 20.4 ± 28.4 | 17.3 ± 19.5 | 21.9 ± 33.2 |
| Disease location - no. (%) | |||
| Small bowel disease | 14 (13.1) | 9 (19.6) | 5 (8.2) |
| Colonic disease | 25 (23.4) | 11 (23.9) | 14 (23.0) |
| Small bowel and colonic disease | 68 (63.5) | 26 (56.5) | 42 (68.9) |
| Prior biologic therapy | |||
| Number of prior anti-TNFs | 2.2 ± 0.9 | 2.3 ± 0.8 | 2.1 ± 0.9 |
| Number of prior biologics | 2.6 ± 1.2 | 2.6 ± 1.1 | 2.6 ± 1.3 |
| ≥ 2 prior anti-TNF agents - no. (%) | 82 (76.7) | 37 (80.4) | 45 (73.8) |
| Prior surgery for Crohn's disease - no. (%) | 63 (58.8) | 29 (63.0) | 34 (55.7) |
| Stoma | 13 (12.1) | 6 (13.0) | 7 (11.5) |
| Ileoanal pouch | 5 (4.7) | 3 (6.5) | 2 (3.3) |
| Draining fistulae at baseline - no. (%) ‡ | 7 (15.2) | ||
| Corticosteroid at induction - no. (%) | 39 (39.4) | 22 (51.1) | 17 (30.4) |
| Prednisone equivalent dose at induction - mg | 11.3 ± 15.4 | 14.9 ± 16.0 | 8.5 (14.4) |
| Concomitant immunosuppressants | 34 (31.7) | 15 (35) | 19 (31.1) |
| Thiopurines | 16 (15.0) | 8 (18.2) | 8 (13.1) |
| Methotrexate | 18 (17.3) | 7 (15.9) | 11 (18.0) |
| Ulcerative colitis | Total population (n=65) | MGH (n=40) | BWH (n=25) |
| Age - yrs | 40.5 ± 13.7 | 40.7 ± 14.3 | 40.3 ± 12.9 |
| Male sex - no (%) | 32 (49.2) | 22 (55.0) | 10 (40.0) |
| Duration of disease - yrs | 10.1 ± 7.0 | 9.1 ± 7.1 | 11.6 ± 6.7 |
| Current smoker - no. (%) | 3 (4.6) | 1 (2.5) | 2 (8.0) |
| Mean SCCAI score ‡ | 6.5 ± 2.7 | ||
| Mean C-reactive protein -mg/litre | 9.8 ± 14.9 | 8.8 ± 12.8 | 11.4 ± 17.9 |
| Disease location - no. (%) | |||
| Rectum and sigmoid only | 8 (12.5) | 6 (15.4) | 2 (8.0) |
| Left colon | 21 (32.8) | 13 (33.3) | 8 (32.0) |
| Pancolitis | 35 (54.6) | 20 (51.3) | 15 (60.0) |
| Number of prior anti-TNFs | 1.9 ± 0.9 | 2.1 ± 0.9 | 1.7 (0.8) |
| ≥ 2 prior anti-TNF agents - no. (%) | 40 (61.5) | 27 (67.5) | 13 (52.0) |
| Corticosteroid at induction - no. (%) | 37 (57.8) | 27 (67.5) | 10 (41.7) |
| Prednisone equivalent dose at induction - mg | 15.9 ± 17.5 | 17.2 ± 16.2 | 13.8 ± 19.1 |
| Concomitant immunosuppressants - no. (%) | 17 (26.6) | 10 (25.6) | 7 (28.0) |
| Thiopurines | 11 (17.2) | 6 (15.4) | 5 (20.0) |
| Methotrexate | 6 (9.4) | 4 (10.3) | 2 (8.0) |
★
Plus–minus values are means ±SD. TNF denotes tumor necrosis factor.
‡
HBI score, SCCAI score and draining fistulae at baseline available for MGH patients only.
¥
Patients with a pouch (n=3) and stoma (n=6) were excluded.